Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Average Rating of “Hold” by Analysts

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) has been assigned an average recommendation of “Hold” from the ten ratings firms that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, six have given a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $9.33.

A number of research analysts recently weighed in on FULC shares. Leerink Partners reissued a “market perform” rating and set a $4.00 price target on shares of Fulcrum Therapeutics in a research report on Thursday, September 12th. Royal Bank of Canada reissued a “sector perform” rating and set a $4.00 target price on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th. Leerink Partnrs lowered Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 12th. HC Wainwright reiterated a “neutral” rating and set a $4.00 price target on shares of Fulcrum Therapeutics in a report on Thursday, November 14th. Finally, Stifel Nicolaus downgraded Fulcrum Therapeutics from a “buy” rating to a “hold” rating and reduced their price objective for the company from $22.00 to $3.00 in a research note on Thursday, September 12th.

Fulcrum Therapeutics Trading Up 7.9 %

NASDAQ FULC opened at $4.35 on Friday. The firm has a market capitalization of $234.63 million, a P/E ratio of -14.03 and a beta of 2.14. The business has a fifty day simple moving average of $3.59 and a 200 day simple moving average of $5.80. Fulcrum Therapeutics has a 12 month low of $2.86 and a 12 month high of $13.70.

Institutional Investors Weigh In On Fulcrum Therapeutics

Several large investors have recently added to or reduced their stakes in FULC. Braidwell LP purchased a new position in shares of Fulcrum Therapeutics in the third quarter worth about $3,817,000. State Street Corp grew its stake in Fulcrum Therapeutics by 61.4% in the 3rd quarter. State Street Corp now owns 1,680,229 shares of the company’s stock valued at $5,998,000 after buying an additional 638,955 shares in the last quarter. Assenagon Asset Management S.A. bought a new stake in Fulcrum Therapeutics during the 2nd quarter valued at $3,084,000. Charles Schwab Investment Management Inc. lifted its position in shares of Fulcrum Therapeutics by 223.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 569,185 shares of the company’s stock worth $2,032,000 after acquiring an additional 393,202 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. bought a new position in shares of Fulcrum Therapeutics in the third quarter worth $721,000. Hedge funds and other institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.